Nektar Therapeutics, NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors

Oct 10, 2007 - Nektar Therapeutics (Nasdaq: NKTR) announced that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics in San Francisco, California on October 25, 2007. The presentations will highlight new results from preclinical trials of NKTR-102 in mouse models of colorectal, lung and breast cancers... Nektar's Press Release-

Broncus Technologies, Encouraging Results Reported on Airway Bypass Procedure , Exhale Drug-Eluting Stent

October 9, 2007 - Broncus Technologies, Inc., a medical device company investigating the airway bypass procedure for the treatment of emphysema, announced that the results of its open-label Exhale® Drug-Eluting Stent feasibility study have been published in the October issue of the Journal of Thoracic and Cardiovascular Surgery. Positive results include a statistically significant reduction in the amount of air trapped in the lungs and an improvement in breathing for patients at six months after the airway bypass procedure... Broncus' Press Release-

Exelixis, Phase II study of XL647 in Patients with Non-Small Cell Lung Cancer

Calif., Oct. 8 , 2007 - Exelixis, Inc. (Nasdaq: EXEL ) announced that data from ongoing phase 2 trials of XL880 and XL647 in papillary renal cell carcinoma and non-small cell lung cancer, respectively, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held October 22-26, 2007 in San Fran cisco... Exelixis' Press Release -

MediciNova Positive Phase IIa Clinical Study Results for MN-221, a Novel Treatment for Status Asthmaticus

Oct 9, 2007 - MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), announced positive results from a Phase IIa clinical study of MN-221, its novel intravenous product candidate for the treatment of status asthmaticus* (acute severe asthma attack)... MediciNova's Press Release -

PTC Therapeutics, Phase 2 Results of PTC124 in Cystic Fibrosis

October 5, 2007 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced encouraging data from a Phase 2 clinical trial of PTC124 in pediatric patients with cystic fibrosis (CF) due to a nonsense mutation... PTC Therapeutics' Press Release -

Inspire, Phase 3 Cystic Fibrosis Trial

Oct. 4, 2007--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced that it has completed patient enrollment in TIGER-1, the first of two planned pivotal Phase 3 clinical trials with denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis*(CF)... Inspire's Press Release -

MedImmune , Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results

Oct. 4 /PRNewswire/ -- MedImmune, Inc. announced results from two important studies presented at the 2007 Infectious Diseases Society of America (IDSA) 45th Annual Meeting adding to the body of knowledge about respiratory syncytial virus* (RSV). RSV is a viral pathogen that produces annual outbreaks usually between fall and spring. While RSV typically manifests cold-like symptoms in healthy children, it can prove to be a very serious respiratory illness for premature infants and is the leading cause of respiratory infections for newborns each year... MedImmune 's Press Release -

Gilead, Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

Oct. 4, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) announced detailed results of its Phase III AIR-CF1 (CP-AI-007) study of aztreonam lysine for inhalation, an investigational therapy in development for the treatment of people with cystic fibrosis* (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa). In this study, a 28-day treatment course of aztreonam lysine improved respiratory symptoms as assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a patient-reported outcome (PRO) tool. Aztreonam lysine also improved pulmonary function in this study, as measured by relative improvement of forced expiratory volume in one second (FEV1), a standard measure of lung function... Gilead's Press Release -

Invacare , new Invacare® XPO2™ extremely portable oxygen concentrator

October 02, 2007 - -At Medtrade 2007, Invacare Corporation (NYSE:IVC) will be launching a series of products and programs that will help providers remain profitable in the new home medical equipment (HME) environment... The Invacare Respiratory Division will introduce the new Invacare^® XPO2^™ extremely portable oxygen concentrator. The XPO2 is the latest introduction to Invacare's proven line of innovative home oxygen technologies... Invacare's Press Release -

development of NOV-002, Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer

October 1, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that Novelos, in collaboration with the Medical University of South Carolina (MUSC), was awarded a $150,000 competitive grant by the National Institutes of Health (NIH) under Phase I of the Small Business Technology Transfer (STTR) program. This grant will support further scientific development of NOV-002, Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track... Novelos' Press Release [PDF] -

Critical Therapeutics, Phase I Clinical Trial of the R(+) Isomer of Zileuton

October 1, 2007 - Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced the initiation of a Phase I clinical trial to assess the safety and tolerability of an oral single dose of the R(+) isomer of zileuton in healthy subjects. R(+) zileuton combined in equal proportion with its mirror image isomer, S(-) zileuton, comprise racemic zileuton, which is the pharmaceutical ingredient in ZYFLO® (zileuton tablets) and ZYFLO CR(TM) (zileuton) extended-release tablets...In addition to asthma, the successful development of the R(+) isomer may also allow for possible development opportunities in other diseases - such as Chronic Obstructive Pulmonary Disease.. Critical Therapeutics' Press Release -

Emphasys Medical, PMA Submission for Bronchial Valve Therapy

Oct. 1, 2007 - Emphasys Medical Inc. announced the submission of a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) requesting regulatory approval to market the Emphasys endobronchial valve, the Zephyr(R) EBV, in the United States. The Zephyr EBV is a minimally invasive and potentially reversible treatment option intended to help patients with emphysema breathe easier...Emphasys Medical's Press Release -

Discovery Laboratories, Surfaxin Process Validation Batches

Oct. 1, 2007 , 2007 - Discovery Laboratories, Inc. (NasdaqGM:DSCO) today announces that its new Surfaxin(r) (lucinactant) process validation batches have demonstrated acceptable stability at six months under Discovery Labs' comprehensive stability testing protocol. This six-month stability data will be included, along with other data and information, in a formal response to the U.S. Food and Drug Administrations' (FDA) April 2006 Approvable Letter for Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants... Discovery Laboratories' Press Release [PDF] -

FASgen, Significant Milestone in Its Cancer Drug Development Program

Oct. 1 , 2007 - FASgen's fatty acid synthase inhibitor (FASi) compounds, led by FAS031, have demonstrated efficacy against every solid tumor xenograft cell line tested, in both orthotopic and flank models: 4 lung tumor cell lines (H460; A549; H1975; LX7); two ovarian; breast; and, colon. In many cases the tumors were eradicated entirely. The compounds have been shown in extensive preclinical studies to be remarkably safe and orally available... FASgen's Press Release -